These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29146922)

  • 41. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
    Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus.
    Kaslow DC; Isaacs SN; Quakyi IA; Gwadz RW; Moss B; Keister DB
    Science; 1991 May; 252(5010):1310-3. PubMed ID: 1925544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural basis for antibody recognition of the NANP repeats in
    Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
    Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
    Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines.
    Duffy PE; Kaslow DC
    Infect Immun; 1997 Mar; 65(3):1109-13. PubMed ID: 9038325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional Characterization and Comparison of
    Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
    Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
    [No Abstract]   [Full Text] [Related]  

  • 47. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Refolding and characterization of a diabody against Pfs25, a vaccine candidate of Plasmodium falciparum.
    Jagannath DK; Valiyaparambil A; Viswanath VK; Hurakadli MA; Kamariah N; Jafer AC; Patole C; Pradhan S; Kumar N; Lakshminarasimhan A
    Anal Biochem; 2022 Oct; 655():114830. PubMed ID: 35944694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
    Huang WC; Deng B; Mabrouk MT; Seffouh A; Ortega J; Long C; Miura K; Wu Y; Lovell JF
    Malar J; 2020 Aug; 19(1):309. PubMed ID: 32859199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine.
    Tiwari S; Goyal AK; Mishra N; Khatri K; Vaidya B; Mehta A; Wu Y; Vyas SP
    J Control Release; 2009 Dec; 140(2):157-65. PubMed ID: 19686788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
    Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
    Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
    Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
    PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
    Front Immunol; 2019; 10():1256. PubMed ID: 31231386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations.
    Bompard A; Da DF; Yerbanga RS; Biswas S; Kapulu M; Bousema T; Lefèvre T; Cohuet A; Churcher TS
    Sci Rep; 2017 Jul; 7(1):6766. PubMed ID: 28754921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25.
    Kaslow DC; Bathurst IC; Isaacs SN; Keister DB; Moss B; Barr PJ
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():175-7. PubMed ID: 1343687
    [No Abstract]   [Full Text] [Related]  

  • 58. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
    Kundu P; Semesi A; Jore MM; Morin MJ; Price VL; Liang A; Li J; Miura K; Sauerwein RW; King CR; Julien JP
    Nat Commun; 2018 Oct; 9(1):4458. PubMed ID: 30367064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural and Vaccine-Induced Acquisition of Cross-Reactive IgG-Inhibiting ICAM-1-Specific Binding of a Plasmodium falciparum PfEMP1 Subtype Associated Specifically with Cerebral Malaria.
    Olsen RW; Ecklu-Mensah G; Bengtsson A; Ofori MF; Lusingu JPA; Castberg FC; Hviid L; Adams Y; Jensen ATR
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29426042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.